Literature DB >> 1677640

Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation.

D Robertson1, V Haile, S E Perry, R M Robertson, J A Phillips, I Biaggioni.   

Abstract

Dopamine beta-hydroxylase (DBH) deficiency is a genetic disorder in which affected patients cannot synthesize norepinephrine, epinephrine, and octopamine in either the central nervous system or the peripheral autonomic neurons. Dopamine acts as a false neurotransmitter in their noradrenergic neurons. Neonates with DBH deficiency have had episodic hypothermia, hypoglycemia, and hypotension, but survivors sometimes cope relatively well until late childhood when overwhelming orthostatic hypotension profoundly limits their activities. The hypotension may be so severe that clonic seizures supervene. Most currently recognized patients are young or middle-aged adults. The diagnosis is established by the observation of severe orthostatic hypotension in a patient whose plasma norepinephrine/dopamine ratio is much less than one.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677640     DOI: 10.1161/01.hyp.18.1.1

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  26 in total

Review 1.  Dysautonomia: perioperative implications.

Authors:  Hossam I Mustafa; Joshua P Fessel; John Barwise; John R Shannon; Satish R Raj; André Diedrich; Italo Biaggioni; David Robertson
Journal:  Anesthesiology       Date:  2012-01       Impact factor: 7.892

2.  Pediatric ptosis as a sign of treatable autonomic dysfunction.

Authors:  Lara Phillips; David Robertson; Mark R Melson; Emily M Garland; Karen M Joos
Journal:  Am J Ophthalmol       Date:  2013-04-24       Impact factor: 5.258

Review 3.  Catecholamine metabolites affected by the copper-dependent enzyme dopamine-beta-hydroxylase provide sensitive biomarkers for early diagnosis of menkes disease and viral-mediated ATP7A gene therapy.

Authors:  Stephen G Kaler; Courtney S Holmes
Journal:  Adv Pharmacol       Date:  2013

Review 4.  Impact of the Autonomic Nervous System on the Skeleton.

Authors:  Florent Elefteriou
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Human dopamine β-hydroxylase promoter variant alters transcription in chromaffin cells, enzyme secretion, and blood pressure.

Authors:  Yuqing Chen; Kuixing Zhang; Gen Wen; Fangwen Rao; Amber P Sanchez; Lei Wang; Juan L Rodriguez-Flores; Manjula Mahata; Sushil K Mahata; Jill Waalen; Michael G Ziegler; Bruce A Hamilton; Daniel T O'Connor
Journal:  Am J Hypertens       Date:  2010-09-02       Impact factor: 2.689

6.  Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure.

Authors:  Yuqing Chen; Gen Wen; Fangwen Rao; Kuixing Zhang; Lei Wang; Juan L Rodriguez-Flores; Amber P Sanchez; Manjula Mahata; Laurent Taupenot; Ping Sun; Sushil K Mahata; Bamidele Tayo; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Daniel T O'Connor
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

7.  Hypertension-related coronary thrombosis: prothrombic role of angiotensin II.

Authors:  C R Spillert; S Sun; M A Miller; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1994-09       Impact factor: 1.798

8.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 9.  Update on the theory and management of orthostatic intolerance and related syndromes in adolescents and children.

Authors:  Julian M Stewart
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-11

10.  The C-1021T polymorphism of dopamine β-hydroxylase is not associated with orthostatic hypotension in a Chinese population.

Authors:  N Lu; J Chen; Y Yuan; X Cong; Y Yang; L Meng; K Sun; R Hui; Y Zheng
Journal:  J Hum Hypertens       Date:  2014-07-03       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.